MFG
NBIX icon

Mendota Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Mendota Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-455
Closed -$62.1K – 278
2024
Q4 		$62.1K Sell
455
-195
-30% -$24.1K 0.04% 134
2024
Q3 		$74.9K Hold
650
– – 0.04% 141
2024
Q2 		$89.5K Sell
650
-100
-13% -$13.7K 0.05% 132
2024
Q1 		$103K Sell
750
-377
-33% -$51.5K 0.06% 125
2023
Q4 		$148K Hold
1,127
– – 0.12% 99
2023
Q3 		$127K Hold
1,127
– – 0.13% 73
2023
Q2 		$106K Buy
+1,127
New +$110K 0.12% 86

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mendota Financial Group's NBIX Position: Q1 2025 in Review

Mendota Financial Group sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 455 shares — an estimated $62.1K sold.

Mendota Financial Group first reported a position in NBIX in Q2 2023 and held it in 7 quarters. The position peaked at $148K in Q4 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Mendota Financial Group reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Mendota Financial Group sold 455 Neurocrine Biosciences shares in Q1 2025, an estimated $62.1K.
  • Mendota Financial Group first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 7 quarters.
  • Mendota Financial Group's Neurocrine Biosciences position peaked at $148K in Q4 2023.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Mendota Financial Group's 13F filing for Q1 2025, filed 22 Apr 2025.